offline
Regeneron Earnings: Slammed On Costs, Cancer Setback — Shares Dive
...
Regeneron Earnings, Sales Miss Estimates
For the first quarter ended March 31, adjusted Regeneron earnings slipped 5% to $4.45 per share. That lagged the average estimate of analysts polled by Zacks Investment Research for Regeneron earnings of $5.52 per share.
Sales advanced 13% to $1.71 billion, but missed estimates for $1.74 billion.
"This negative result was largely anticipated after Sanofi, on April 26, reported lower collaboration antibody revenues than previously anticipated by Regeneron consensus, but was exacerbated by higher product costs and R&D spend in the quarter," Leerink's Porges said.
...
https://www.investors.com/news/technolog...yptr=yahoo
![[Bild: REGNc1dl1525.png]](https://finviz.com/publish/050719/REGNc1dl1525.png)
...
Regeneron Earnings, Sales Miss Estimates
For the first quarter ended March 31, adjusted Regeneron earnings slipped 5% to $4.45 per share. That lagged the average estimate of analysts polled by Zacks Investment Research for Regeneron earnings of $5.52 per share.
Sales advanced 13% to $1.71 billion, but missed estimates for $1.74 billion.
"This negative result was largely anticipated after Sanofi, on April 26, reported lower collaboration antibody revenues than previously anticipated by Regeneron consensus, but was exacerbated by higher product costs and R&D spend in the quarter," Leerink's Porges said.
...
https://www.investors.com/news/technolog...yptr=yahoo
__________________
